Affiliations: [a] Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran | [b] Research Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran | [c] Iran National Tumor Bank, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Correspondence:
[*]
Corresponding author: Jamshid Karimi, Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Tel.: +98 8138276293; Fax: +98 8138380208; E-mail:jamshidkarimi2013@gmail.com
Abstract: BACKGROUND: Ovarian cancer is one of the important challenges in
the field of gynecologic oncology because of some problems in understanding
its etiology and pathogenesis. Receptor for advanced glycation end products
(RAGE) is a multiligand trans-membranous receptor which is upregulated in
some human cancers. Mechanisms of RAGE involvement in carcinogenesis of
ovarian cancer are unknown. OBJECTIVE: This study aimed to investigate the expression of RAGE
in ovarian cancers and its association with clinicopathological characteristics. METHODS: The RAGE expression level in ovarian cancer and
corresponding noncancerous tissues were analyzed by real time quantitative
RT-PCR and immunohistochemistry techniques. RESULTS: Results indicated that RAGE gene was overexpressed in
ovarian cancer tissue compared with adjacent noncancerous tissue (p <
0.001). A significant association between RAGE expression and tumor size (p
= 0.04), depth of stromal invasion (p = 0.031), lymphovascular invasion (p =
0.041) and stage of cancer (p = 0.041) was observed. The receiver operating
characteristic (ROC) analyses yielded the area under the curve (AUC) values
of 0.86 for RAGE in discriminating ovarian cancer samples from non-cancer
controls. CONCLUSIONS: In conclusion overexpression of RAGE in ovarian cancer
may be a useful biomarker to predict tumor progression.
Keywords: Carcinoma, ovarian cancer, receptor for advanced glycation end products, tumor
